BioCentury
ARTICLE | Finance

Iowa to IPO

Cancer vaccine company NewLink files for IPO

January 3, 2011 8:00 AM UTC

Cancer vaccine company NewLink Genetics Corp., founded in 1999 by practicing oncologist and company CEO and CSO Charles Link, has filed to raise up to $86.3 million in an IPO.

The Iowa biotech's lead candidate is HyperAcute Pancreas, an allogeneic cancer vaccine containing irradiated pancreatic tumor cells modified to express alpha 1,3-galactosyltransferase. It is in Phase III testing as an adjuvant in surgically resected pancreatic cancer, and has Orphan Drug designation and Fast Track status...